Full-Time

Competitive Intelligence Manager

Cardiovascular

Updated on 8/22/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$124.3k - $168.2k/yr

+ Annual bonus + Stock-based long-term incentives

Deerfield, IL, USA + 1 more

More locations: Thousand Oaks, CA, USA

Hybrid

Minimum of two days on site is highly encouraged; travel of 15–20% is required.

Bachelor's, Master's, MBA, PhD, Associate's, Incomplete

Category
Business & Strategy (1)
Required Skills
Marketing
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree, or a master's degree and 2 years of consulting and/or competitive intelligence experience, or a bachelor's degree and 4 years of consulting and/or competitive intelligence experience, or an associate's degree and 8 years of consulting and/or competitive intelligence experience, or a high school diploma/GED and 10 years of consulting and/or competitive intelligence experience.
  • Experience with life science consulting work in cardiovascular is preferred.
  • Familiarity with the biopharmaceutical industry is preferred.
  • Relevant cardiovascular experience through prior project work or disease-area knowledge is preferred.
  • Prior strategy or management consulting experience in the biopharmaceutical industry, including roles of increasing responsibility, is preferred.
  • Ability to think strategically and analyze data to support critical business decisions.
  • Oral, written, and presentation skills sufficient to explain complex concepts clearly to varied audiences.
  • Project management skills sufficient to manage multiple simultaneous projects and data sources.
  • Analytical skills, including understanding the advantages and limitations of different analytical approaches and studies.
  • Ability to work collaboratively in a team-based environment.
  • Strong understanding of developments and trends in the oncology space, competitive dynamics, and unmet medical needs is preferred.
Responsibilities
  • Lead intelligence-gathering activities for United States and global marketing teams supporting multiple assets across the cardiovascular portfolio.
  • Act as a strategic thought partner to collaborators across disease-area, brand, corporate, and other cross-functional teams.
  • Synthesize information from multiple sources to develop strategic insights and points of view on competitive developments, implications for Amgen, and required actions.
  • Manage changing priorities across several key customers in a highly cross-functional environment.
  • Develop relationships with global and regional teams to define business problems and develop integrated analysis plans using standard methodologies.
  • Apply structured problem solving to collect, analyze, and report competitive intelligence using primary and secondary data sources.
  • Educate customers on the impact of changing market dynamics on their businesses from a competitive-intelligence perspective.
  • Organize and facilitate strategic and red-team exercises to generate competitive insights and company plans.
  • Coordinate and facilitate competitive-intelligence collection at major medical conferences and congresses, and attend and support competitive-intelligence debrief activities.
  • Manage a network of primary data sources, including vendors and Amgen employees, to enable project delivery.
  • Collaborate with fellow competitive-intelligence leads.
  • Understand and synthesize competitive-intelligence research findings while maintaining accuracy, relevance, and quality in deliverables and communicating the level of evidence to key partners.
  • Present in-depth analyses and summaries of results regularly, interpreting and communicating results with recommendations to key stakeholders.
  • Abide by and strictly enforce Amgen's competitive-intelligence legal and ethical guidelines with internal colleagues and agencies.
  • Travel 15–20% as required.
Desired Qualifications
  • Advanced degree (PhD, MS, or MBA) with a focus on life sciences and business.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2-$39.4 billion after Q2 strength.
  • MariTide entered nine Phase 3 trials in 2026, targeting obesity and diabetes.
  • Repatha’s Q2 2026 sales reached $953 million, boosted by VESALIUS-CV data.

What critics are saying

  • FDA still seeks TAVNEOS withdrawal; Amgen requested a hearing on June 1, 2026.
  • Delaware jury found Amgen willfully infringed Harbour BioMed’s patent on June 12, 2026.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack the franchise.

What makes Amgen unique

  • Amgen’s six growth drivers grew 26% in Q2 2026, supplying nearly 70% sales.
  • Repatha, Evenity, Uplizna, and Imdelltra all posted 37%-115% Q2 2026 growth.
  • Hyderabad’s 2027 Science and Innovation Center deepens Amgen’s global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.